[1]李佳丽,刘耀,曾东风,等.硼替佐米联合地塞米松和沙利度胺治疗多发性骨髓瘤的临床研究[J].第三军医大学学报,2012,34(24):2515-2517.
　Li Jiali,Liu Yao,Zeng Dongfeng,et al.Bortezomib combined with dexamethasone and thalidomide in treatment of multiple myeloma: report of 58 cases[J].J Third Mil Med Univ,2012,34(24):2515-2517.
点击复制

硼替佐米联合地塞米松和沙利度胺治疗多发性骨髓瘤的临床研究(/HTML )
分享到：

《第三军医大学学报》[ISSN:1000-5404/CN:51-1095/R]

卷:
34卷
期数:
2012年第24期
页码:
2515-2517
栏目:
论著
出版日期:
2012-12-30

文章信息/Info

Title:
Bortezomib combined with dexamethasone and thalidomide in treatment of multiple myeloma: report of 58 cases
作者:
李佳丽; 刘耀; 曾东风; 李杰平; 陈幸华; 张曦; 彭贤贵; 孔佩艳
第三军医大学新桥医院血液科，全军血液病中心
Author(s):
Li Jiali;  Liu Yao;  Zeng Dongfeng;  Li Jieping;  Chen Xinghua;  Zhang Xi;  Peng Xiangui;  Kong Peiyan
Department of Hematology, Xinqiao Hospital, Third Military Medical University, Chongqing，400037, China
关键词:
多发性骨髓瘤; 硼替佐米; 疗效; 不良反应
Keywords:
multiple myeloma;  bortezomib;  efficacy;  adverse effects
分类号:
R733.3;R977.11;R979.1
文献标志码:
A
摘要:
目的      观察硼替佐米联合地塞米松和沙利度胺(VTD)方案对多发性骨髓瘤(multiple myeloma，MM)患者的临床疗效。      方法      收集2008年4月至2012年2月于本院接受VTD方案治疗的58例MM患者临床资料，并以同期30例传统长春新碱＋蒽环类＋地塞米松+沙利度胺（VADT）方案化疗的MM患者作为对照，分析病情转归及不良反应。患者均完成2个及以上疗程治疗。      结果      随访6个月至2年的MM患者：①VTD用于初治和复发和（或）难治MM患者的总有效率显著高于VADT组（63.8% vs 40.0%，P<0.05）。VTD方案中初治患者治疗总有效率显著高于复发和（或）难治患者（77.8% vs 40.9%，P<0.05)；VTD组治疗初治MM的有效率也明显高于VADT组（36.0%），差异有统计学意义(P<0.05)。VTD治疗复发和（或）难治MM的有效率与VADT组（60.0%）无差异（P>0.05)。VTD组内轻链型、非轻链型MM患者疗效无显著统计学差异（P>0.05)。②VTD治疗不良反应主要有消化道症状、感染、周围神经病变及血小板减少。      结论      硼替佐米联合地塞米松和沙利度胺治疗MM缓解率高，副作用少且一般较轻微，可首选用于治疗初治及复发和（或）难治MM患者。
Abstract:
Objective      To observe the efficiency of combination of bortezomib plus dexamethasone and thalidomide (VTD) in treatment of multiple myeloma (MM).       Methods      From April 2008 and February 2012, fifty-eight MM patients underwent VTD treatment in Xinqiao Hospital. A contemporary cohort of 30 MM patients receiving VADT（vincristine+anthracycline+dexamethasone+thalidomide） chemotherapy was set as the control group. The prognosis of disease and adverse effects were analyzed. All subjects were taken chemotherapy in two or more cycles of treatment. All patients were followed up for 6 months to 2 years.       Results      The total effective rate of the VTD group was 63.8%, significantly higher than of the VADT group (40.0%, P<0.05). In VTD treatment, response was 77.8% in newly diagnosed group and 40.9% in relapsed/refractory group (P<0.01). The rate of response did not differ between VTD and VADT treatments among relapsed/refractory MM patients (P>0.05), but was higher with VTD treatment than with VADT treatment for newly diagnosed MM patients (77.8% vs 36.0%, P<0.05). There was no statistical significance between light chain patients and non-light chain patients in VTD group（P>0.05). The adverse effects of VTD were mainly gastrointestinal symptoms infection, peripheral neuropathy and thrombocytopenia.       Conclusion      VTD treatment is associated with higher rate of remission in treatment of MM, and therefore can be used as a first-line option for newly diagnosed and relapsed/refractory patients.

相似文献/References:

[1]谢燕,喻秀丽,童立纺.硼替佐米对A549细胞增殖及p21、p27表达的影响[J].第三军医大学学报,2012,34(17):1775.
　Xie Yan,Yu Xiuli,Tong Lifang.Anti-proliferation effect of proteasome inhibitor bortezomib in human lung adenocarcinoma A549 cells[J].J Third Mil Med Univ,2012,34(24):1775.
[2]段海玲,熊玮,杨和平,等.误诊为肺癌骨转移的多发性骨髓瘤1例[J].第三军医大学学报,2008,30(10):931.
[3]张超,陈晓红.Syndecan-1在多发性骨髓瘤发病中作用的研究进展[J].第三军医大学学报,2005,27(18):1891.
[4]谢家印,王东,李梦侠,等.APE1/Ref-1 siRNA抑制多发性骨髓瘤骨髓基质细胞IL-6及IL-8分泌的体外研究[J].第三军医大学学报,2009,31(19):1850.
　XIE Jia-yin,WANG Dong,LI Meng-xia,et al.APE1/Ref-1 siRNA inhibits IL-6 and IL-8 secretion by cultured bone marrow stromal cells isolated from multiple myeloma patients[J].J Third Mil Med Univ,2009,31(24):1850.
[5]谢家印,杜佳,李梦侠,等.RNA干扰骨髓基质细胞和/或骨髓瘤细胞APE1表达对共培养骨髓瘤细胞增殖及凋亡的影响[J].第三军医大学学报,2011,33(10):1008.
　Xie Jiayin,Du Jia,Li Mengxia,et al.Effects of RNA interference inhibiting APE1 expression in bone marrow stromal cells and/or U266 cells on proliferation and apoptosis of co-cultured U266[J].J Third Mil Med Univ,2011,33(24):1008.
[6]高力,张曦,高蕾,等.不同来源基质细胞对骨髓瘤KM3细胞增殖和凋亡的影响[J].第三军医大学学报,2009,31(10):879.
　GAO Li,ZHANG Xi,GAO Lei,et al.Effect of stromal cells derived from different origins on proliferation and apoptosis of KM3 cells[J].J Third Mil Med Univ,2009,31(24):879.
[7]樊锐太,胡勇,刘俊启,等.硼替佐米对U87胶质瘤放射增敏及细胞周期分布的影响[J].第三军医大学学报,2012,34(08):758.
　Fan Ruitai,Hu Yong,Liu Junqi,et al.Effect of bortezomib on radiosensitivity of U87 glioma and distribution of cell cycle[J].J Third Mil Med Univ,2012,34(24):758.
[8]李颖,陈建斌,宋君君,等.甲基化修饰致PCDH10基因在多发性骨髓瘤中沉默[J].第三军医大学学报,2012,34(09):817.
　Li Ying,Chen Jianbin,Song Junjun,et al.Methylation induces protocadherin-10 silence in multiple myeloma[J].J Third Mil Med Univ,2012,34(24):817.
[9]侯慧明,张红宾,刘林.IgG型多发性骨髓瘤自体造血干细胞移植后复发合并急性淋巴细胞白血病1例[J].第三军医大学学报,2013,35(13):1361.
[10]张亮,杜佳,周立为,等.依布硒诱导多发性骨髓瘤细胞凋亡及其机制的研究[J].第三军医大学学报,2014,36(02):110.
　Zhang Liang,Du Jia,Zhou Liwei,et al.Ebselen induces apoptosis in human multiple myeloma cell line U226[J].J Third Mil Med Univ,2014,36(24):110.
[11]杨再林,张勇,张伶,等.硼替佐米联合化疗对多发性骨髓瘤的疗效与相关血液学指标分析[J].第三军医大学学报,2010,32(09):975.
　Yang Zailin,Zhang Yong,Zhang Ling,et al.Effect of bortezomib in combination with chemotherapy on multiple myeloma and change in its hematological indexes[J].J Third Mil Med Univ,2010,32(24):975.

更新日期/Last Update: 2012-12-19